- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05535972
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
March 10, 2024 updated by: GlaxoSmithKline
A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (Trelegy Ellipta) in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD.
The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
460
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- GSK Investigational Site
-
Chengdu, China
- GSK Investigational Site
-
Fuzhou, China
- GSK Investigational Site
-
Guangzhou, China, 500000
- GSK Investigational Site
-
Hangzhou, China, 310005
- GSK Investigational Site
-
Hefei, China
- GSK Investigational Site
-
Lanzhou, China
- GSK Investigational Site
-
Mianyang, China
- GSK Investigational Site
-
Nanchang, China, 330006
- GSK Investigational Site
-
Panzhihua, China
- GSK Investigational Site
-
Shanghai, China, 201299
- GSK Investigational Site
-
Shenyang, China
- GSK Investigational Site
-
Shenyang, China, 110000
- GSK Investigational Site
-
Shenzhen, China
- GSK Investigational Site
-
Taizhou, China, 318000
- GSK Investigational Site
-
Tianjin, China
- GSK Investigational Site
-
Weifang, China
- GSK Investigational Site
-
Wuhan, China
- GSK Investigational Site
-
Xianyang, China
- GSK Investigational Site
-
Yiwu, China
- GSK Investigational Site
-
-
Fujian
-
Jinjiang, Fujian, China, 362299
- GSK Investigational Site
-
-
Guangdong
-
Dongguan, Guangdong, China, 523326
- GSK Investigational Site
-
Guangzhou, Guangdong, China, 510120
- GSK Investigational Site
-
Huizhou, Guangdong, China, 516000
- GSK Investigational Site
-
Huizhou, Guangdong, China, 516001
- GSK Investigational Site
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- GSK Investigational Site
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750001
- GSK Investigational Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant must be 40 years or above of age inclusive, at the time of signing the informed consent.
- Participants with a documented physician diagnosis of COPD.
- CAT greater than or equal to (≥) 10.
- Existing COPD Maintenance Treatment. Participants currently receiving one of the maintenance therapies given below who have been prescribed it continually for at least 12 weeks prior to screening (Visit 1): Inhaled Corticosteroids/ Long-Acting Beta-2-Agonists (ICS/LABA) (single or multiple inhalers); Long-Acting Muscarinic Antagonist (LAMA)/LABA (single or multiple inhalers); Free combination of inhaled corticosteroids (ICS), LAMA, LABA.
- Current or former cigarette smokers with a history of cigarette smoking history ≥10 pack-years at screening.
- Trelegy is prescribed under the discretion of clinical physicians with medical records providing documentation of a Trelegy prescription in daily practice.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria:
- Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- Prescribed with Trelegy within one year prior to screening (Visit 1).
- Participants who, in the opinion of the treating investigator, are chronic users of oral corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening). Chronic use is defined as more than 14 days continuous use during the 12 weeks prior to Visit 1.
- Participants with any life-threatening condition i.e. low probability, in the opinion of the investigator, of 3-month survival due to severity of COPD or comorbid condition.
- Participants with unstable COPD. Participants with resolution of an exacerbation less than 2 weeks prior to Visit 1. Participants may be rescreened 2 weeks after resolution of exacerbation (exacerbation is defined as: requiring treatment with antibiotics and/or systemic steroids or hospitalization; resolution is defined as: 2 weeks after all symptoms have resolved and any medicines to treat the exacerbation have finished).
- Participants who need more than 3 liter per minute (L/min) supplemental oxygen at rest at screening.
- Other diseases/abnormalities: Participants with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
- Participant received any investigational drug in other clinical trial within four weeks or 5 half-lives prior to this study whichever is longer.
- Any conditions or illnesses listed in the section of contraindications in the Summary of Product Characteristics (SmPC) of Trelegy, i.e., hypersensitivity to the active substances of TRELEGY ELLIPTA.
- Participants with known COVID-19 positive contacts within the past 14 days.
- Inability to read: In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants receiving TRELEGY ELLIPTA
Participants will receive FF/UMEC/VI, inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) for 12 weeks.
|
FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in COPD Assessment Test (CAT) score
Time Frame: Baseline (Day 1) and at Week 12
|
CAT is a validated 8-item questionnaire developed for use in routine clinical practice to measure the health status of patients with COPD.
Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40.
Higher scores indicated greater disease impact.
|
Baseline (Day 1) and at Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of Modified Medical Research Council (mMRC) Score
Time Frame: Baseline (Day 1) and at Week 12
|
The mMRC will be used to assess the breathlessness state of the patient before and after the treatment.
Participants will be scored on a scale of 0-4 depending on their disability due to shortness of breath from 0 (no impact) to 4 (worst possible impact).
Higher scores indicated greater disease impact.
|
Baseline (Day 1) and at Week 12
|
Change from baseline in Pre-dose Forced Expiratory Volume in 1 second (FEV1)
Time Frame: Baseline (Day 1) and at Week 12
|
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second.
|
Baseline (Day 1) and at Week 12
|
Percentage of participants having ≥ 2 unit decrease in CAT score from baseline at week 12.
Time Frame: Baseline (Day 1) and at Week 12
|
CAT is a validated 8-item questionnaire developed for use in routine clinical practice to measure the health status of patients with COPD.
Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40.
Higher scores indicated greater disease impact.
A change of 2 unit compared to baseline is considered as the minimum clinical meaningful difference.
|
Baseline (Day 1) and at Week 12
|
Number of participants with Trelegy related Adverse Events (AEs)
Time Frame: Up to Week 12
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
|
Up to Week 12
|
Number of participants with Serious Adverse Events (SAEs)
Time Frame: Up to Week 12
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as judged by physician.
|
Up to Week 12
|
Number of participants with AEs that lead to the discontinuation of Trelegy Ellipta
Time Frame: Up to week 12
|
Up to week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 14, 2022
Primary Completion (Actual)
September 25, 2023
Study Completion (Actual)
September 25, 2023
Study Registration Dates
First Submitted
September 7, 2022
First Submitted That Met QC Criteria
September 7, 2022
First Posted (Actual)
September 10, 2022
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 10, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 217658
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on FF/UMEC/VI
-
GlaxoSmithKlineRecruiting
-
GlaxoSmithKlineRecruiting
-
GlaxoSmithKlineParexelCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveChina
-
GlaxoSmithKlineActive, not recruitingPulmonary Disease, Chronic ObstructiveIndia
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, Chile, Romania, Canada
-
GlaxoSmithKlineCompletedAsthmaAustralia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom